CY1120936T1 - Αναστολεις πεπτιδιου toy μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν το κυτταρο για χρηση εις την αγωγη της ραγοειδιτιδας - Google Patents
Αναστολεις πεπτιδιου toy μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν το κυτταρο για χρηση εις την αγωγη της ραγοειδιτιδαςInfo
- Publication number
- CY1120936T1 CY1120936T1 CY181100963T CY181100963T CY1120936T1 CY 1120936 T1 CY1120936 T1 CY 1120936T1 CY 181100963 T CY181100963 T CY 181100963T CY 181100963 T CY181100963 T CY 181100963T CY 1120936 T1 CY1120936 T1 CY 1120936T1
- Authority
- CY
- Cyprus
- Prior art keywords
- inhibitors
- treatment
- urbititis
- cell
- transfer path
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αφορά στην χρήση αναστολέων πρωτεϊνικής κινάσης και πλέον συγκεκριμένα στην χρήση αναστολέων της πρωτεϊνικής κινάσης c-Jun αμινο-τελικής κινάσης, (πολυ-)πεπτιδίων αναστολέα JNK, χιμαιρικών πεπτιδίων ή νουκλεϊκών οξέων τα οποία κωδικοποιούν τα ίδια, όπως επίσης φαρμακευτικών συνθέσεων οι οποίες περιέχουν τα ίδια για την αγωγή μη-χρόνιων ή χρόνιων φλεγμονωδών νόσων του οφθαλμού, όπως τα φλεγμονώδη νοσήματα των βλεφάρων, του επιπεφυκότα, του κερατοειδή, του σκληρού χιτώνα, του υαλώδους σώματος, του ραγοειδή, του ακτινωτού σώματος, του χοριοειδούς χιτώνα, του κογχικού οστού, του δακρυϊκού αδένα, ή της ίριδας συγκεκριμένα όπου η φλεγμονώδης νόσος επιλέγεται από κριθαράκι, χαλάζιο, επιπεφυκίτιδα, κερατίτιδα, σκληρίτιδα, επισκληρίτιδα, ενδοφθαλμίτιδα, πανοφθαλμίτιδα, ιρίτιδα, ραγοειδίτιδα, κυκλίτιδα, χοριοειδίτιδα, κογχική φλεγμονή, αμφιβληστροειδίτιδα και/ή μυοσίτιδα των οφθαλμικών μυών.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2010/006284 WO2012048721A1 (en) | 2010-10-14 | 2010-10-14 | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases |
| EP2011000307 | 2011-01-25 | ||
| EP11775734.4A EP2627346B1 (en) | 2010-10-14 | 2011-10-14 | Cell-permeable peptide inhibitors of the jnk signal transduction pathway for use in the treatment of uveitis |
| EP14004427.2A EP2902035B1 (en) | 2010-10-14 | 2011-10-14 | Cell-permeable peptide inhibitors of the JNK signal transduction pathway for use in the treatment of inflammatory eye diseases. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120936T1 true CY1120936T1 (el) | 2019-12-11 |
Family
ID=44862926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181100963T CY1120936T1 (el) | 2010-10-14 | 2018-09-18 | Αναστολεις πεπτιδιου toy μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν το κυτταρο για χρηση εις την αγωγη της ραγοειδιτιδας |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP2902035B1 (el) |
| CY (1) | CY1120936T1 (el) |
| DK (2) | DK2627346T3 (el) |
| ES (2) | ES2575226T3 (el) |
| HK (2) | HK1187266A1 (el) |
| PL (2) | PL2627346T3 (el) |
| WO (1) | WO2012048893A1 (el) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040082509A1 (en) | 1999-10-12 | 2004-04-29 | Christophe Bonny | Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| WO2007031098A1 (en) | 2005-09-12 | 2007-03-22 | Xigen S.A. | Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| WO2009143864A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| WO2009143865A1 (en) | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2010072228A1 (en) | 2008-12-22 | 2010-07-01 | Xigen S.A. | Novel transporter constructs and transporter cargo conjugate molecules |
| WO2011160653A1 (en) | 2010-06-21 | 2011-12-29 | Xigen S.A. | Novel jnk inhibitor molecules |
| JP5857056B2 (ja) | 2010-10-14 | 2016-02-10 | ザイジェン インフラメーション エルティーディー | 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用 |
| WO2013091670A1 (en) * | 2011-12-21 | 2013-06-27 | Xigen S.A. | Novel jnk inhibitor molecules for treatment of various diseases |
| CN105307670A (zh) | 2013-06-26 | 2016-02-03 | 埃克西金炎症有限公司 | Jnk信号转导途径的细胞渗透肽抑制剂用于治疗多种疾病的新用途 |
| WO2015197098A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2014206427A1 (en) | 2013-06-26 | 2014-12-31 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2015197097A1 (en) | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use for jnk inhibitor molecules for treatment of various diseases |
| CA2947508A1 (en) * | 2014-06-26 | 2015-12-30 | Xigen Inflammation Ltd. | New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| DE102016111708A1 (de) | 2016-06-27 | 2017-12-28 | Heiko Schmidt | Gelenkanordnung, vorgefertigte Baugruppe sowie Verfahren zur Herstellung einer vorgefertigten Baugruppe einer Gelenkanordnung |
| CN108060223A (zh) * | 2017-12-29 | 2018-05-22 | 北京泱深生物信息技术有限公司 | Atf2基因的新应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0454781B1 (en) | 1989-01-23 | 1998-12-16 | Chiron Corporation | Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| ATE200625T1 (de) | 1992-10-09 | 2001-05-15 | Advanced Tissue Sciences Inc | Leberreservezellen |
| ATE365808T1 (de) | 1995-07-28 | 2007-07-15 | Marie Curie Cancer Care | Transportproteine und deren verwendungen |
| WO2004054501A2 (en) * | 2002-11-18 | 2004-07-01 | Celgene Corporation | Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
| US10045953B2 (en) * | 2006-07-06 | 2018-08-14 | Case Western Reserve University | Ceramide composition and method of use |
| WO2009143865A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases |
| WO2009143864A1 (en) * | 2008-05-30 | 2009-12-03 | Xigen S.A. | Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases |
| CN102365093A (zh) * | 2009-03-30 | 2012-02-29 | 参天制药株式会社 | 用于视网膜疾病的预防剂或治疗剂和使用JNK(c-Jun氨基末端激酶)抑制肽预防或治疗视网膜疾病的方法以及所述肽的用途 |
-
2011
- 2011-10-14 ES ES11775734.4T patent/ES2575226T3/es active Active
- 2011-10-14 WO PCT/EP2011/005172 patent/WO2012048893A1/en active Application Filing
- 2011-10-14 EP EP14004427.2A patent/EP2902035B1/en active Active
- 2011-10-14 DK DK11775734.4T patent/DK2627346T3/en active
- 2011-10-14 ES ES14004427T patent/ES2688030T3/es active Active
- 2011-10-14 PL PL11775734.4T patent/PL2627346T3/pl unknown
- 2011-10-14 PL PL14004427T patent/PL2902035T3/pl unknown
- 2011-10-14 DK DK14004427.2T patent/DK2902035T3/en active
- 2011-10-14 EP EP11775734.4A patent/EP2627346B1/en active Active
-
2014
- 2014-01-10 HK HK14100332.1A patent/HK1187266A1/zh not_active IP Right Cessation
-
2015
- 2015-11-09 HK HK15111042.8A patent/HK1210056A1/xx unknown
-
2018
- 2018-09-18 CY CY181100963T patent/CY1120936T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2627346B1 (en) | 2016-03-23 |
| PL2902035T3 (pl) | 2019-04-30 |
| DK2902035T3 (en) | 2018-09-24 |
| WO2012048893A1 (en) | 2012-04-19 |
| EP2902035A1 (en) | 2015-08-05 |
| PL2627346T3 (pl) | 2016-11-30 |
| ES2688030T3 (es) | 2018-10-30 |
| DK2627346T3 (en) | 2016-06-13 |
| HK1210056A1 (en) | 2016-04-15 |
| HK1187266A1 (zh) | 2014-04-04 |
| EP2627346A1 (en) | 2013-08-21 |
| EP2902035B1 (en) | 2018-06-20 |
| ES2575226T3 (es) | 2016-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120936T1 (el) | Αναστολεις πεπτιδιου toy μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν το κυτταρο για χρηση εις την αγωγη της ραγοειδιτιδας | |
| AR076796A1 (es) | Proteinas de union al antigeno. composicion farmaceutica. uso. procedimiento. | |
| ES2910831T3 (es) | Software de guiado y planificación quirúrgicos para el tratamiento de astigmatismos | |
| Liu et al. | Trehalose induces autophagy against inflammation by activating TFEB signaling pathway in human corneal epithelial cells exposed to hyperosmotic stress | |
| Goyal et al. | Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease | |
| PE20201264A1 (es) | Variantes de capsides de virus adenoasociados y metodos de uso de estas | |
| PE20190129A1 (es) | Capsides variantes de virus adenoasociados y metodos de uso de estas | |
| WO2007104541A3 (en) | Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders | |
| JOP20170147B1 (ar) | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة | |
| BRPI0519508A2 (pt) | análogos de aminopirazina para tratamento de glaucoma e outras doenças ou condições mediadas por rho cinase | |
| UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
| KR20190142776A (ko) | 6-6 융합 바이사이클릭 헤테로아릴 화합물 및 lats 억제제로서의 이의 용도 | |
| CY1114725T1 (el) | Χρηση αναστολεων πεπτιδιου του μονοπατιου μεταγωγης σηματος jnk οι οποιοι διαπερνουν τα κυτταρα για τη θεραπευτικη αγωγη διαφορων καρδιαγγειακων νοσων | |
| UA120039C2 (uk) | Селективно заміщені сполуки хіноліну | |
| Li et al. | Slit2 promotes angiogenic activity via the Robo1-VEGFR2-ERK1/2 pathway in both in vivo and in vitro studies | |
| Che et al. | High glucose-induced epithelial-mesenchymal transition contributes to the upregulation of fibrogenic factors in retinal pigment epithelial cells | |
| JP2013540770A5 (el) | ||
| EA201790889A1 (ru) | Офтальмологический раствор | |
| Labib et al. | Therapeutic targets in allergic conjunctivitis | |
| Choi et al. | The effect of TNF-α blocker HL036337 and its best concentration to inhibit dry eye inflammation | |
| Zhang et al. | Characterisation of Cl‐transporter and channels in experimentally induced myopic chick eyes | |
| Zhu et al. | PKR promotes choroidal neovascularization via upregulating the PI3K/Akt signaling pathway in VEGF expression | |
| Sumi et al. | IOP-lowering effect of isoquinoline-5-sulfonamide compounds in ocular normotensive monkeys | |
| D'Souza et al. | Comparative analysis of two femtosecond LASIK platforms using iTRAQ quantitative proteomics | |
| Vu et al. | Calpains as mechanistic drivers and therapeutic targets for ocular disease |